SG11201700387QA - Toxic rna inhibitors self-assembled in situ - Google Patents

Toxic rna inhibitors self-assembled in situ

Info

Publication number
SG11201700387QA
SG11201700387QA SG11201700387QA SG11201700387QA SG11201700387QA SG 11201700387Q A SG11201700387Q A SG 11201700387QA SG 11201700387Q A SG11201700387Q A SG 11201700387QA SG 11201700387Q A SG11201700387Q A SG 11201700387QA SG 11201700387Q A SG11201700387Q A SG 11201700387QA
Authority
SG
Singapore
Prior art keywords
situ
assembled
rna inhibitors
toxic rna
self
Prior art date
Application number
SG11201700387QA
Inventor
Matthew D Disney
Suzanne G Rzuczek
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of SG11201700387QA publication Critical patent/SG11201700387QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A61K47/557—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells the modifying agent being biotin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SG11201700387QA 2014-07-18 2015-07-17 Toxic rna inhibitors self-assembled in situ SG11201700387QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462026266P 2014-07-18 2014-07-18
PCT/US2015/040902 WO2016011348A1 (en) 2014-07-18 2015-07-17 Toxic rna inhibitors self-assembled in situ

Publications (1)

Publication Number Publication Date
SG11201700387QA true SG11201700387QA (en) 2017-02-27

Family

ID=55079084

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201700387QA SG11201700387QA (en) 2014-07-18 2015-07-17 Toxic rna inhibitors self-assembled in situ

Country Status (9)

Country Link
US (2) US10220031B2 (en)
EP (1) EP3169404A4 (en)
JP (2) JP6461306B2 (en)
CN (1) CN106714908A (en)
AU (1) AU2015289524A1 (en)
CA (1) CA2955428A1 (en)
IL (1) IL250113A0 (en)
SG (1) SG11201700387QA (en)
WO (1) WO2016011348A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10220031B2 (en) * 2014-07-18 2019-03-05 The Scripps Research Institute Toxic RNA inhibitors self-assembled in situ
WO2018098297A1 (en) * 2016-11-28 2018-05-31 The Scripps Research Institute Precise small molecule recognition of a toxic cug rna repeat expansion
AU2018374389A1 (en) 2017-11-30 2020-05-07 Arrakis Therapeutics, Inc. Nucleic acid-binding photoprobes and uses thereof
WO2022051405A1 (en) * 2020-09-02 2022-03-10 Promega Corporation Nucleic acid modifying reagents and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008218939B2 (en) * 2007-02-23 2014-05-08 The Research Foundation Of State University Of New York RNA targeting compounds and methods for making and using same
WO2012050896A2 (en) * 2010-09-29 2012-04-19 Kansas State University Research Foundation Protease selective supramolecular assemblies
US20140050778A1 (en) * 2010-12-28 2014-02-20 University Of Rochester Nucleic acid binding compounds, methods of making, and use thereof
WO2013138662A1 (en) * 2012-03-16 2013-09-19 4S3 Bioscience, Inc. Antisense conjugates for decreasing expression of dmpk
WO2014036395A1 (en) * 2012-08-30 2014-03-06 The Scripps Research Institute SMALL MOLECULES TARGETING REPEAT r(CGG) SEQUENCES
US10220031B2 (en) * 2014-07-18 2019-03-05 The Scripps Research Institute Toxic RNA inhibitors self-assembled in situ

Also Published As

Publication number Publication date
AU2015289524A1 (en) 2017-02-02
JP2017522323A (en) 2017-08-10
JP2019068831A (en) 2019-05-09
CA2955428A1 (en) 2016-01-21
IL250113A0 (en) 2017-03-30
EP3169404A4 (en) 2018-02-07
US20170143703A1 (en) 2017-05-25
WO2016011348A1 (en) 2016-01-21
CN106714908A (en) 2017-05-24
US20190151310A1 (en) 2019-05-23
US10220031B2 (en) 2019-03-05
JP6461306B2 (en) 2019-01-30
EP3169404A1 (en) 2017-05-24
US10471057B2 (en) 2019-11-12

Similar Documents

Publication Publication Date Title
IL280941A (en) Modified double-stranded rna agents
IL287113A (en) Smyd inhibitors
IL252386A0 (en) Targeted rna editing
IL249928B (en) Corrodible downhole article
SG11201608605QA (en) Methods and means for enhancing rna production
IL246785A0 (en) Benzimidazol-2-amines as midh1 inhibitors
PL3108009T3 (en) Methods and compositions for dna profiling
PT3215147T (en) Neuro-attenuating ketamine and norketamine compounds, derivatives thereof, and methods
HK1226398A1 (en) Benzimidazol-2-amines as midh1 inhibitors
IL248895A0 (en) Phosphatidylinositol -kinase inhibitors
IL250113A0 (en) Toxic rna inhibitors self-assembled in situ
IL248936A0 (en) Small molecule lfa-1 inhibitors
PL3186332T3 (en) Method for hydraulic fracturing
GB201420832D0 (en) Location method
EP3157591C0 (en) In situ tissue engineering
ZA201503784B (en) Tunneling method
SG11201605798WA (en) Demolishing method
GB2522039B (en) I-beam
ZA201705645B (en) Methods and compositions for dna profiling
IL235470A0 (en) Mikveh and method for constructing thereof
GB201418154D0 (en) Inhibitors
GB201421947D0 (en) Elecroplating method and composition
GB201407865D0 (en) Nucleases